Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Atossa Therapeutics ( (ATOS) ) has provided an announcement.
On September 26, 2025, Atossa Therapeutics, Inc. released an updated corporate presentation. The release of this presentation is part of Atossa’s ongoing efforts to keep stakeholders informed, although it does not impact any filings with the U.S. Securities and Exchange Commission.
The most recent analyst rating on (ATOS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Atossa Therapeutics stock, see the ATOS Stock Forecast page.
Spark’s Take on ATOS Stock
According to Spark, TipRanks’ AI Analyst, ATOS is a Underperform.
Atossa Therapeutics’ stock score is weighed down by significant financial challenges, including ongoing operational losses and negative cash flow, despite a debt-free balance sheet. Technical indicators suggest short-term overbought conditions, while the valuation remains unattractive due to a lack of profitability and dividends. Although the earnings call provided some positive guidance on cost reductions and clinical progress, these are overshadowed by the company’s financial instability.
To see Spark’s full report on ATOS stock, click here.
More about Atossa Therapeutics
Average Trading Volume: 1,072,282
Technical Sentiment Signal: Strong Sell
Current Market Cap: $106.6M
See more data about ATOS stock on TipRanks’ Stock Analysis page.